Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566585 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
A Phase 1 study, sponsored by BlueSphere Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT07566585 is a Phase 1 study that is actively recruiting participants, run by BlueSphere Bio. The registered enrollment target is 19 participants.
The verdict
NCT07566585, a Phase 1 study, is actively recruiting participants, sponsored by BlueSphere Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
Interventions
- DRUG SOC+ BSB-2002
- DRUG SOC+BSB-2002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07566585
The ClinicalTrials.gov registry entry for NCT07566585 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BlueSphere Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SOC+ BSB-2002 is the first listed.
NCT07566585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07566585 about?
NCT07566585 is a clinical study titled "Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation". The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
What is the current status of trial NCT07566585?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2026-04-21. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07566585?
The interventions under investigation include: SOC+ BSB-2002 (DRUG), SOC+BSB-2002 (DRUG).
Who is sponsoring clinical trial NCT07566585?
This trial is sponsored by BlueSphere Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.